Total Payments
$925,146
2024 Payments
$4,531
Companies
10
Transactions
41
Medicare Patients
956
Medicare Billing
$222,452
Payment Breakdown by Category
Research$907,120 (98.1%)
Consulting$8,580 (0.9%)
Other$4,846 (0.5%)
Travel$4,156 (0.4%)
Food & Beverage$431.93 (0.0%)
Education$12.49 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $907,120 | 14 | 98.1% |
| Consulting Fee | $8,580 | 4 | 0.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,846 | 3 | 0.5% |
| Travel and Lodging | $4,156 | 11 | 0.4% |
| Food and Beverage | $431.93 | 8 | 0.0% |
| Education | $12.49 | 1 | 0.0% |
Payments by Type
Research
$907,120
14 transactions
General
$18,027
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $903,951 | 7 | $0 (2023) |
| Incyte Corporation | $4,880 | 4 | $0 (2021) |
| Eli Lilly and Company | $4,403 | 16 | $0 (2020) |
| ABBVIE INC. | $3,375 | 1 | $0 (2022) |
| PFIZER INC. | $3,330 | 3 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,956 | 2 | $0 (2020) |
| Servier BioInnovation | $1,331 | 3 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,240 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $647.25 | 3 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $32.81 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,531 | 4 | PFIZER INC. ($3,200) |
| 2023 | $3,375 | 2 | Merck Sharp & Dohme LLC ($2,135) |
| 2022 | $5,205 | 2 | ABBVIE INC. ($3,375) |
| 2021 | $2,639 | 1 | Incyte Corporation ($2,639) |
| 2020 | $2,671 | 5 | Regeneron Pharmaceuticals, Inc. ($1,956) |
| 2019 | $4,309 | 16 | Eli Lilly and Company ($4,192) |
| 2018 | $902,349 | 9 | Merck Sharp & Dohme Corporation ($899,986) |
| 2017 | $67.03 | 2 | Incyte Corporation ($34.22) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $570.55 | Research |
| Study: S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations | ||||||
| 12/17/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $570.55 | Research |
| Study: S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations | ||||||
| 10/31/2024 | PFIZER INC. | TRAZIMERA | — | In-kind items and services | $3,200.00 | Research |
| Study: NIROGACESTAT CLINICAL PUBLICATION PROGRAM | ||||||
| 10/14/2024 | Servier BioInnovation | — | — | Cash or cash equivalent | $190.00 | Research |
| Study: S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations | ||||||
| 12/11/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 03/31/2023 | Janssen Pharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $1,240.00 | General |
| 10/24/2022 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| 06/24/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| 04/02/2021 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,639.00 | General |
| 09/09/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $868.37 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/14/2020 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $211.34 | General |
| 01/30/2020 | Novartis Pharmaceuticals Corporation | BLZ495X (Drug) | — | In-kind items and services | $285.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 01/30/2020 | Novartis Pharmaceuticals Corporation | BLZ495X (Drug) | — | In-kind items and services | $219.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 01/22/2020 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $1,087.29 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/01/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $117.67 | General |
| 05/14/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $590.76 | General |
| 05/14/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $171.13 | General |
| 05/14/2019 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $79.97 | General |
| 05/14/2019 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $14.98 | General |
| 04/13/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $110.38 | General |
| 04/10/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $1,131.20 | General |
| 04/10/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $1,029.96 | General |
| 04/10/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $343.33 | General |
| 04/10/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $252.46 | General |
| 04/10/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $176.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers | Merck Sharp & Dohme Corporation | $899,986 | 5 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,956 | 2 |
| S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations | Servier BioInnovation | $1,331 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $504.00 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $143.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 303 | 555 | $266,469 | $58,867 |
| 2022 | 6 | 257 | 596 | $277,305 | $62,838 |
| 2021 | 4 | 204 | 537 | $249,351 | $59,198 |
| 2020 | 6 | 192 | 459 | $199,913 | $41,549 |
Total Patients
956
Total Services
2,147
Medicare Billing
$222,452
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 187 | 377 | $201,298 | $42,022 | 20.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 82 | $23,326 | $7,791 | 33.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 27 | 27 | $20,101 | $3,867 | 19.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 20 | $11,904 | $2,707 | 22.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $3,588 | $936.74 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 11 | $2,972 | $813.19 | 27.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 23 | 27 | $3,280 | $730.86 | 22.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 149 | 428 | $219,285 | $48,238 | 22.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 23 | 74 | $20,942 | $6,061 | 28.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $20,036 | $4,094 | 20.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 15 | $8,566 | $2,247 | 26.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 14 | 14 | $4,311 | $1,198 | 27.8% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 28 | 36 | $4,165 | $999.58 | 24.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 140 | 434 | $214,998 | $50,320 | 23.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 28 | 28 | $18,372 | $4,280 | 23.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 44 | $12,452 | $3,676 | 29.5% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 20 | 31 | $3,529 | $922.25 | 26.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 102 | 315 | $150,074 | $27,419 | 18.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 73 | $20,659 | $6,018 | 29.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 27 | 27 | $13,944 | $3,534 | 25.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 15 | $7,779 | $2,351 | 30.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 13 | 14 | $3,962 | $1,240 | 31.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 14 | 15 | $3,495 | $987.15 | 28.2% |
About Dr. Aung Naing, MD
Dr. Aung Naing, MD is a Internal Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104837590.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aung Naing, MD has received a total of $925,146 in payments from pharmaceutical and medical device companies, with $4,531 received in 2024. These payments were reported across 41 transactions from 10 companies. The most common payment nature is "" ($907,120).
As a Medicare-enrolled provider, Naing has provided services to 956 Medicare beneficiaries, totaling 2,147 services with total Medicare billing of $222,452. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Houston, TX
- Active Since 08/10/2006
- Last Updated 04/05/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1104837590
Products in Payments
- KEYTRUDA (Biological) $899,986
- LIBTAYO (Biological) $1,956
- BLZ495X (Drug) $504.00
- MCS110 (Drug) $143.25
- IBRANCE (Drug) $12.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Houston
Stephen Pappas, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Mohamed Othman, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Miguel Escobar, M.d, M.D
Internal Medicine — Payments: $924,228
Internal Medicine $924,228
Dr. Christie Ballantyne, Md, MD
Internal Medicine — Payments: $815,154
Internal Medicine $815,154
John Heymach, M.d, M.D
Internal Medicine — Payments: $786,947
Internal Medicine $786,947
Dr. Maen Abdelrahim, Md, MD
Internal Medicine — Payments: $748,784
Internal Medicine $748,784